TY - JOUR T1 - Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 91 LP - 100 DO - 10.21873/cgp.20170 VL - 17 IS - 1 AU - JOHN WEN-CHENG CHANG AU - CHUN-LIANG SHIH AU - CHIH-LIANG WANG AU - JI-DUNG LUO AU - CHIH-WEI WANG AU - JIA-JUAN HSIEH AU - CHIA-JUNG YU AU - CHIUAN-CHIAN CHIOU Y1 - 2020/01/01 UR - http://cgp.iiarjournals.org/content/17/1/91.abstract N2 - Background/Aim: Circulating mRNA can be a useful source of cancer biomarkers. We took advantage of direct transcriptomic analysis in plasma RNA to identify novel mRNA markers for non-small cell lung cancer (NSCLC). Patients and Methods: Plasma RNA from NSCLC patients and healthy individuals was profiled with cDNA-mediated annealing, selection, extension and ligation (DASL) microarrays. The microarray results were further validated in plasma RNA. Results: Through RNA profiling and online database mining, four gene transcripts were filtered as candidate markers of NSCLC. After validation, the PCTAIRE-1 transcript was identified as a circulating mRNA marker. The diagnostic potential of PCTAIRE-1 was evaluated by receiver operating characteristic curve analysis, which gave a sensitivity and specificity of 60% and 85%, respectively. In addition, high plasma PCTK1 levels were also correlated with poor progression-free survival (p=0.008). Conclusion: Circulating mRNA can be profiled with the DASL assay. From the profile, PCTAIRE-1 RNA in the plasma we discovered as a novel diagnostic/prognostic biomarker and an indicator of poor survival in NSCLC patients. ER -